The only bendamustine approved for indication of both CLL and B-cell NHL in China currently. In 2020, guidelines published by the Chinese Society of Clinical Oncology (CSCO) have recommended bendamustine as the first- and second- line treatment of multiple subtypes of B-cell lymphoma.